logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12599557 B1

PDFFull Text
Date of Patent:
Apr. 14, 2026

Filed:

Apr. 25, 2020

Liposomal sustained-release compositions containing a therapeutic drug and use thereof

Applicants:

Tlc Biopharmaceuticals, Inc., South San Francisco, CA (US);

Taiwan Liposome Co., Ltd., Taipei, TW;

Inventors:

Yun-Long Tseng, Taipei, TW;

Hsin-Yi Chiu, Taipei, TW;

Assignees:

TLC BIOPHARMACEUTICALS, INC., South San Francisco, CA (US);

TAIWAN LIPOSOME CO., LTD., Taipei City, TW;

Attorney:

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Primary Examiner:

Robert A Wax

Assistant Examiner:

John W Lippert, III

Int. Cl.
CPC ...
A61K 9/127 (2025.01); A61K 31/045 (2006.01); A61K 31/085 (2006.01); A61K 31/135 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/196 (2006.01); A61K 31/245 (2006.01); A61K 31/397 (2006.01); A61K 31/40 (2006.01); A61K 31/405 (2006.01); A61K 31/4168 (2006.01); A61K 31/439 (2006.01); A61K 31/445 (2006.01); A61K 31/46 (2006.01); A61K 31/4745 (2006.01); A61K 31/485 (2006.01); A61K 31/5415 (2006.01); A61K 31/5513 (2006.01); A61K 31/5517 (2006.01); A61K 31/573 (2006.01); A61K 31/616 (2006.01); A61K 47/24 (2006.01); A61K 47/28 (2006.01);
U.S. Cl.
CPC ...
A61K 9/127 (2013.01); A61K 31/045 (2013.01); A61K 31/085 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/245 (2013.01); A61K 31/397 (2013.01); A61K 31/40 (2013.01); A61K 31/405 (2013.01); A61K 31/4168 (2013.01); A61K 31/439 (2013.01); A61K 31/445 (2013.01); A61K 31/46 (2013.01); A61K 31/4745 (2013.01); A61K 31/485 (2013.01); A61K 31/5415 (2013.01); A61K 31/5513 (2013.01); A61K 31/5517 (2013.01); A61K 31/573 (2013.01); A61K 31/616 (2013.01); A61K 47/24 (2013.01); A61K 47/28 (2013.01);
Abstract

Provided is a liposomal sustained-release composition comprising a therapeutic agent and one or more lipids. The therapeutic agent and total lipids are present in the liposomal sustained-released composition at a predetermined ratio. The liposomal sustained-release composition achieves a desired therapeutic effect while avoiding undesired side effects. The therapeutic agent is stably entrapped in the liposomes of the composition and sustainably released therefrom. This liposomal formulation for the therapeutic agent demonstrates an improved release profile.

Find Patent Forward Citations

Loading…